Insights

Efficacy and Safety of Rucaparib: A Focus on ARIEL3
December 12, 2017 – 
Robert L. Coleman, MD, offers insight regarding the findings from ARIEL3, with rucaparib in the switch maintenance setting of ovarian cancer.
Efficacy and Safety of Olaparib and Niraparib in Switch Maintenance
December 12, 2017 – 
Robert L. Coleman, MD, examines efficacy and safety data from NOVA with niraparib, and Study 19 and SOLO-2 with olaparib in ovarian cancer.
Delaying Recurrence in Ovarian Cancer
December 05, 2017 – 
Robert L. Coleman, MD, discusses the risk of recurrence in ovarian cancer and explains the concept of switch maintenance.
Role of PARP Inhibition in Ovarian Cancer
December 05, 2017 – 
Robert L. Coleman, MD, outlines the rationale for PARP inhibition in ovarian cancer and for examining the efficacy of PARP inhibitors outside of populations with germline BRCA mutations.
Expertise on the Ovarian Cancer Healthcare Team
November 28, 2017 – 
Robert L. Coleman, MD, explains the value of having a gynecologic oncologist weigh in on discussions involving treatment and clinical trial results.
Understanding Ovarian Cancer
November 28, 2017 – 
Robert L. Coleman, MD, highlights the incidence of ovarian cancer and discusses why the prevalence of the disease is increasing.
Raising the Bar on Cardiovascular Benefit
November 15, 2017 – 
Expert John Anderson, MD, offers his perspective on the importance of newer medications based on longer-term outcomes and costs.
Sequencing Therapies in NSCLC
November 13, 2017 – 
Benjamin P. Levy, MD, reviews sequencing therapies in non–small cell lung cancer and shares his outlook on the future of treatments.
Anti-Angiogenesis in NSCLC
November 13, 2017 – 
Benjamin P. Levy, MD, describes the rationale for targeting angiogenesis therapy in lung cancer, including the method of action for bevacizumab and ramucirumab and utilizing anti-angiogenesis to boost treatment efficacy.
Examining Cardiovascular Outcomes Trials
November 10, 2017 – 
Expert John Anderson, MD, emphasizes the importance of evidence-based care in type 2 diabetes and weighing the clinical data appropriately.
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome to the new and improved AJMC.com, the premier managed markets network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!